The Influence of Human Leukocyte Antigen and IL-10 Gene Polymorphisms on Hepatitis B Virus Outcome
Hepatitis Monthly: ,
12 (5); 320-325 Article Type: Review Article
January 17, 2012
April 29, 2012
A, et al. The Influence of Human Leukocyte Antigen and IL-10 Gene Polymorphisms on Hepatitis B Virus Outcome,
Online ahead of Print
Context: The clinical outcome of hepatitis B virus (HBV) infection is variable, ranging from spontaneous recovery to an inactive carrier state, chronic hepatitis, occult HBV infection, liver cirrhosis, or hepatocellular carcinoma. Evidence Acquisition: This variable pattern and clinical outcomes of the infection were mainly determined by virological and host genetic factors. Since the most of host genetic factors associated with HBV infection have currently focused on human leukocyte antigen (HLA) associations and interleukin (IL)-10 gene polymorphisms, this review focuses on the recent progresses in these issues to provide prognostic markers for the outcome of HBV infection. Results: A study on serum levels of IL-10 in occult HBV infected patients reported that the higher level of IL-10 production may suppress function of the immune system against HBV in patients with occult HBV infection. IL-10 promoter polymorphism at position -592 is associated with susceptibility to occult HBV infection. Conclusions: Findings of this study suggest that the host HLA polymorphism is an important factor in determining outcome of HBV infection but regarding IL-10 gene promoter polymorphisms, we are still have a long way to achieve a de?nite conclusion.
Implication for health policy/practice/research/medical education: This article provides prognostic markers including HLA and IL-10 polymorphisms for determining the outcome of HBV infection. Ramezani A, Banifazl M, Mamishi S, So?an M, Eslamifar A, Aghakhani A, The In?uence of Human Leukocyte Antigen and IL-10 Gene Polymorphisms on Hepatitis B Virus Outcome. Hepat Mon. 2012;12(5):320-5. DOI: 10.5812/hepatmon.6094 Please cite this paper as:
Copyright © 2012 Kowsar Corp. All rights reserved.
© 0, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.